Efek Penghambatan Aktivitas Enzim Polo-Like Kinase 1 (PLK1) Pada Pembelahan Mitosis Sel Kanker Serviks

Hartono; Hasri; Ika Yustisia; Rusdina Bte Ladju; Irma Rapi; Tiara Putri Amelia; Nur Putri Apriliani Basri; Eka Risdayanti; St. Sulfia Afdalia

doi:10.35965/eco.v22i2.1975

Authors

Hartono Jurusan Biologi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Negeri Makassar
Hasri Jurusan Kimia, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Negeri Makassar, Makassar
Ika Yustisia Bagian Biokimia, Fakultas Kedokteran, Universitas Hasanuddin, Makassar
Rusdina Bte Ladju Bagian Patologi Anatomi, Fakultas Kedokteran, Universitas Hasanuddin, Makassar
Irma Rapi Jurusan Biologi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Negeri Makassar, Makassar
Tiara Putri Amelia Jurusan Biologi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Negeri Makassar, Makassar
Nur Putri Apriliani Basri Jurusan Biologi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Negeri Makassar, Makassar
Eka Risdayanti Jurusan Kimia, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Negeri Makassar, Makassar
St. Sulfia Afdalia Jurusan Kimia, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Negeri Makassar, Makassar

DOI:

https://doi.org/10.35965/eco.v22i2.1975

Keywords:

PLK1, Mitosis, Sel Kanker Serviks, Hela, BI2536

Downloads

Download data is not yet available.

References

Cheng, M. W., Wang, B. C., Weng, Z. Q., & Zhu, X. W. (2012). Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta histochemica, 114(5), 503-509.

Dewi, F., Jiapaer, S., Kobayashi, A., Hazawa, M., Ikliptikawati, D. K., Hartono, Sabit, H., Nakada, M., & Wong, R. W. (2021). Nucleoporin TPR (translocated promoter region, nuclear basket protein) upregulation alters MTOR-HSF1 trails and suppresses autophagy induction in ependymoma. Autophagy, 17(4), 1001–1012.

Giordano, A., Liu, Y., Armeson, K., Park, Y., Ridinger, M., Erlander, M., Reuben, J., Britten, C., Kappler, C., Yeh, E., & Ethier, S. (2019). Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PloS one, 14(11), e0224420.

Hartono, Hazawa, M., Lim, K.S. et al. (2019). Nucleoporin Nup58 localizes to centrosomes and mid-bodies during mitosis. Cell Div 14, 7.

Jeong, S. B., Im, J. H., Yoon, J. H., Bui, Q. T., Lim, S. C., Song, J. M., Shim, Y., Yun, J., Hong, J., & Kang, K. W. (2018). Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of TamoxifenResistant Breast Cancer. Molecular cancer therapeutics, 17(4), 825–837.

Lin P., Wen D.Y., Dang Y.W., He Y., Yang H., Chen G. (2018). Comprehensive and integrative analysis reveals the diagnostic, clinicopathological and prognostic significance of polo-Like kinase 1 in hepatocellular carcinoma. Cell. Physiol. Biochem ;47:925–947.

Liu Z, Sun Q, Wang X. PLK1, A Potential Target for Cancer Therapy. Transl Oncol. 2017 Feb;10(1):22-32. doi: 10.1016/j.tranon.2016.10.003. Epub 2016 Nov 24. PMID: 27888710; PMCID: PMC5124362.

Karimi Dermani, F., Azizi Jalilian, F., Hossienkhani, H., Ezati, R., & Amini, R. (2019). siRNA Delivery Technology for Cancer Therapy: Promise and Challenges. Acta Medica Iranica, 57(2), 83-93.

Montaudon, E., Nikitorowicz-Buniak, J., Sourd, L., Morisset, L., El Botty, R., Huguet, L., Dahmani, A., Painsec, P., Némati, F., Vacher, S., Chemlali, W., Masliah-planchon, J., Château-Joubert, S., Rega, C., Leal, M.F., Simigdala, N., Pancholi, S., Ribas, R., Nicolas, A., Meseure, D., VincentSalomon, A., Reyes, C., Rapinat, A., Gentien, D., Larcher, T., Bohec, M., Baulande, S., Bernard, V., Decaudin, D., Coussy, F., Le Romancer, M., Dutertre, G., Tariq, Z., Cottu, P., Driouch, K., Bièche, I., Martin, L., & Marangoni, E. (2020). PLK1 inhibition exhibits strong anti-tumoral activity in CCND1- driven breast cancer metastases with acquired palbociclib resistance. Nature Communications, 11.

Remitha N. P. S. I., RompisA. Y., YaniM. V. W., WigunaI. G. W. W., SadvikaI. G. A. S., & PutraI. G. M. A. D. (2020). SiRNA Berbasis Aptamer-PLEGP1800 Enkapsulasi Chitosan: Literature Review Penatalaksanaan Triple Negative Breast Cancer. Journal of Health Science and Prevention, 4(2), 68-78.

Sharifiaghdam M, Shaabani E, Sharifiaghdam Z, De Keersmaecker H, De Rycke R, De Smedt S, Faridi-Majidi R, Braeckmans K and Fraire JC. (2021). Enhanced siRNA Delivery and Selective Apoptosis Induction in H1299 Cancer Cells by Layer-by-Layer-Assembled Se Nanocomplexes: Toward More Efficient Cancer Therapy. Front. Mol. Biosci. 8:639184.

Smith, L., Farzan, R., Ali, S. et al. (2017). The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation. Sci Rep 7, 16115.

Serrano-Sevilla, I., Artiga, Á., Mitchell, S. G., De Matteis, L., & de la Fuente, J. M. (2019). Natural Polysaccharides for siRNA Delivery: Nanocarriers Based on Chitosan, Hyaluronic Acid, and Their Derivatives. Molecules (Basel, Switzerland), 24(14), 2570.

Turner NC, Ro J, Andre F, Loi S, Verma S, H. I. (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 373:209–19.

Ueda, A., Oikawa, K., Fujita, K. et al. (2019). Therapeutic potential of PLK1 inhibition in triple-negative breast cancer. Lab Invest 99, 1275–1286.

Zhao, S., Geng, Y., Cao, L., Yang, Q., Pan, T., Zhou, D., Liu, J., Shi, Z., & Zhang, J. (2021). Deciphering the performance of polo-like kinase 1 in triple-negative breast cancer progression according to the centromere protein U-phosphorylation pathway. American journal of cancer research, 11(5), 2142–2158.

Zhao, S., Geng, Y., Cao, L., Yang, Q., Pan, T., Zhou, D., Liu, J., Shi, Z., & Zhang, J. (2021). Deciphering the performance of polo-like kinase 1 in triple-negative breast cancer progression according to the centromere protein U-phosphorylation pathway. American journal of cancer research, 11(5), 2142–2158